Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -57.87% is 63% above its 5-year average of -156.50%, near the high end of its 5-year range (-876.02%–-27.40%).
As of the fiscal period ended Friday, July 31, 2026. 59.48% above its 12-month average of -142.82%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-07-31): -57.87%.
RETURN ON EQUITY (ROE)
-57.87%
RETURN ON EQUITY (ROE) AVG TTM
-142.82%
RETURN ON EQUITY (ROE) AVG 3Y
-149.70%
RETURN ON EQUITY (ROE) AVG 5Y
-156.50%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+59.48%
CURRENT VS 3Y AVG
+61.34%
CURRENT VS 5Y AVG
+63.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-60.73%
vs the sector median at left
Clearmind Medicine Inc.
Market Cap
$1.11M
Return on Equity (ROE)
-57.87%
TTM Avg
-142.82%
3Y Avg
-149.70%
5Y Avg
-156.50%
Market Cap
$1.14M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
Market Cap
$1.17M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
Market Cap
$1.02M
Return on Equity (ROE)
-93.97%
TTM Avg
234.49%
3Y Avg
123.23%
5Y Avg
1171.22%
Market Cap
$888387.00
Return on Equity (ROE)
-334.41%
TTM Avg
-290.71%
3Y Avg
-280.75%
5Y Avg
-198.19%
Market Cap
$885939.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$878396.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$1.36M
Return on Equity (ROE)
-253.57%
TTM Avg
334.28%
3Y Avg
134.39%
5Y Avg
95.16%
Market Cap
$1.37M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.11M | -57.87% | -142.82% | -149.70% | -156.50% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -11.85% | -6.20% | 47.36% | 47.36% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 558.67% | 54.46% | -8.27% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -93.97% | 234.49% | 123.23% | 1171.22% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -334.41% | -290.71% | -280.75% | -198.19% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | N/A | -255.88% | -273.58% | -200.54% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | -253.57% | 334.28% | 134.39% | 95.16% |
| Genprex, Inc. (GNPX)vs › | $1.37M | -111.51% | -753.43% | -507.39% | -356.28% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -77.23% | -124.66% | -168.43% | -110.88% |
ROE
-57.9%
ROA
-44.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -57.87% |
| 2026-04-30 | -68.76% |
| 2026-01-31 | -80.62% |
| 2025-10-31 | -230.75% |
| 2025-07-31 | -276.09% |
| 2025-04-30 | -152.06% |
| 2025-01-31 | -117.89% |
| 2024-10-31 | -121.49% |
| 2024-07-31 | -174.95% |
| 2024-04-30 | -108.83% |
| 2024-01-31 | -119.26% |
| 2023-10-31 | -876.02% |
| 2023-07-31 | -287.87% |
| 2023-04-30 | -292.04% |
| 2023-01-31 | -196.90% |
| 2022-04-30 | -640.71% |
| 2022-01-31 | -248.02% |
| 2021-10-31 | -99.66% |
| 2021-07-31 | -27.40% |
| 2021-04-30 | -26.15% |
| 2021-01-31 | -93.92% |
| 2020-10-31 | -61.39% |
| 2020-07-31 | -42.26% |
| 2020-04-30 | -29.68% |
| 2020-01-31 | -130.92% |
| 2019-10-31 | -102.75% |
| 2019-07-31 | -183.66% |
| 2019-04-30 | -166.44% |
| 2019-01-31 | -113.79% |
| 2018-10-31 | -108.11% |
| 2018-07-31 | -42.01% |
